Scientists from Duke University found a monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths.
The research is published in The Lancet Respiratory Medicine and was conducted by Thomas Holland et al.
The therapy, tixagevimab/cilgavimab, was developed and deployed quickly in response to the pandemic.
In the study, the phase 3 clinical trial included 1,455 patients and took place at 81 sites on four continents.
Patients were infused with tixagevimab/cilgavimab or a placebo, in addition to remdesivir and other standard care.
By day 90, sustained recovery was achieved by 87% of people who were given tixagevimab/cilgavimab and 84% of placebo group participants.
Mortality was lower by nearly 4% in the tixagevimab/cilgavimab group.
The team says one out of every three patients who would have died without the treatment survived after receiving the monoclonal antibodies.
That’s a remarkable signal for the benefit and suggests that this and other similar treatments may save lives in patients with severe COVID-19.
The team says monoclonal antibodies are a full-spectrum treatment. They have a role in the prevention, treatment of early disease, and hospitalized respiratory failure.
The researchers are hopeful this could be another class of medications for use in hospitals for COVID patients.
If you care about COVID, please read studies about drug combo that could effectively fight COVID-19, and vegetables and coffee could protect against COVID-19.
For more information about COVID, please see recent studies about common drug that may reduce your risk of COVID-19 infection, and results showing new antiviral drug 10 times more effective against COVID-19.
Copyright © 2022 Knowridge Science Report. All rights reserved.
